INTERPACE BIOSCIENCES, INC. (IDXG) Form S-1/A — Oct 30, 2026
Interpace Biosciences filed an S-1/A for a firm-commitment offering of 3,100,000 shares priced at $6.00-$7.00 per share, versus a last OTCID sale price of $5.72, with estimated net proceeds of $17.9 million ($20.8 million with a 465,000-share over-allotment). Lake Street Capital Markets and Laidlaw & Company are underwriting with a 6.0% discount and 90-day lock-ups. The offering is contingent on Nasdaq approving the company's uplisting application under ticker IDXG, moving from the OTCID. The company completed a 1-for-5 reverse split on August 27, 2026 primarily to meet Nasdaq's minimum bid price requirement.
Key figures
- Cash Position
- $2,688 thousand as of June 30, 2026; $20,617 thousand as adjusted for offering
- Gross Proceeds
- approximately $17.9 million net ($20.8 million with full over-allotment)
- Offering Price
- $6.00-$7.00 (assumed midpoint $6.50)
- Shares Offered
- 3100000
- Shares Outstanding
- 5901962
- Lockup Period
- 90 days
- Last Sale Price
- $5.72 (OTCID, Oct 29, 2026)
- Net Income2025
- $24,575 thousand
- Dilution Per Share
- $2.03
- Reverse Split Ratio
- 1-for-5 (effective Aug 27, 2026)
- Post Offering Shares
- 9001962
- Over Allotment Shares
- 465000
- Pe Investor Ownership
- approximately 79% held by two private equity funds
- Underwriting Discount
- 6.0% of gross proceeds ($0.39/share)
- Thyroid Pro Forma Revenue2025
- $34.8 million
- Thyroid Pro Forma Adjusted EBITDA2025
- $4.4 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.